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Abstract
Matrix metalloproteinase (MMP)–mediated degrada-
tion of the extracellular matrix is a major factor for
tumor development and expansion. This study ana-
lysed MMP-10 protein expression and activity in
human lung tumors of various grade, stage, and type
to address the relationship between MMP-10 and
tumor characteristics and to evaluate MMP-10 as a
therapeutic target in non small cell lung carcinoma
(NSCLC). Unlike the majority of MMPs, MMP-10 was
located in the tumor mass as opposed to tumor
stroma. MMP-10 protein was observed at low levels
in normal human lung tissues and at significantly
higher levels in all types of NSCLC. No correlation was
observed between MMP-10 protein expression and
tumor type, stage, or lymph node invasion. To discrim-
inate between active and inactive forms of MMP-10
in samples of human NSCLC, we have developed an
ex vivo fluorescent assay. Measurable MMP-10 activity
was detected in 42 of 50 specimens of lung cancer and
only 2 of 10 specimens of histologically normal lung
tissue. No relationship was observed between MMP-10
activity levels and clinicopathologic characteristics.
Our results suggest that MMP-10 is expressed and
active at high levels in human NSCLC compared to
normal lung tissues, and, as such, is a potential target
for the development of novel therapeutics for lung
cancer treatment.
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Introduction
The term non small cell lung cancer (NSCLC) covers a
group of different histopathologic characteristics. A number
of features of NSCLC at presentation, namely, primary
tumor size, regional lymph node involvement, presence of
metastases, and tumor grade, have been shown to be
related to survival. Early-stage NSCLC, without distant
metastases or heavy regional nodal involvement, may be
amenable to surgical resection. The role of adjuvant che-
motherapy in this setting is becoming more established, but
response to chemotherapy, whether adjuvant or palliative, is
often poor and may relate to the pathologic heterogeneity of
NSCLC among other factors. As a consequence, a better
understanding of the molecular pathology of NSCLC, determi-
nation of novel tumor markers, and identification of targets for
therapeutic exploitation are central to improving diagnosis
and treatment.
In order that a tumor may grow, spread, and metastasise, it
must possess the ability to breakdown and degrade both the
extracellular matrix (ECM) and basement membranes, pro-
mote an angiogenic response, evade immune surveillance,
and avoid elimination [1]. Numerous proteolytic enzymes have
been implicated in these processes, most prominent among
which are the matrix metalloproteinases (MMPs) [2–4]. The
MMPs are a family of at least 24 structurally related zinc-
dependent endopeptidases central to tumor invasion, metas-
tasis, angiogenesis, and malignant cell proliferation [5–7].
Historically, the MMPs were classified into subgroups based
on their specificity for ECM proteins (collagenases, gelati-
nases, matrilysins, stromelysins, and so on), which is reflected
in their names [1,5–7]. However, as the number of MMPs
identified and their respective substrates has grown, a sequen-
tial numbering system for their identity is now being adopted,
and the MMPs are now grouped according to their structure [1].
Currently, the MMPs are classified into eight distinct groups,
with MMP-10 now being classified into the simple hemopexin
domain structural class [1].
All MMPs are produced as inactive zymogens (proMMPs),
which must be subsequently activated by removal of the
propeptide domain to generate catalytically active MMPs
[1,4,5,8,9]. With the exception of membrane-type MMPs
(MT-MMPs), this conversion of inactive proMMP to active
MMP occurs extracellularly. Activation of MMPs is regulated
at two levels within tissues: transcriptionally in response
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to cytokines and growth factors [10] and proteolytically at
the level of proMMP activation [5]. Once secreted and
activated, MMP activity is regulated in situ by endogenous
inhibitors termed tissue inhibitors of metalloproteinase
(TIMPs) [5]. Therefore, within tissues, the balance between
proMMP, active MMP, and TIMPs determines the overall
MMP activity [5].
Several studies have addressed the expression of the
stromelysin subgroup of MMPs in NSCLC to ascertain their
role in tumor development and progression, and as prog-
nostic markers [11–13]. A strong expression of MMP-3
(stromelysin-1) and MMP-11 (stromelysin-3) is observed in
the stromal compartment of NSCLC [11–13]. The observa-
tion that MMP-3 is expressed throughout the majority of
these tumors suggested that it may be a central regulator
of local growth of the neoplastic cell mass [11]. Conversely,
MMP-11 expression is related to local lymph node tumor
invasion [12,13]. In contrast to MMP-3 and MMP-11, the role
of MMP-10 (stromelysin-2) in human NSCLC has not been
extensively evaluated.
Although MMP-10 is closely related to MMP-3 with re-
spect to structure and substrate specificity [14,15], differ-
ences in inducibility, activity, and cellular distribution exist,
suggesting distinct roles for both MMP-3 and MMP-10
[8,16–19]. MMP-10 has a relatively broad substrate speci-
ficity, including proMMPs, ECM proteins, proteoglycans,
glycoproteins, and collagens [1,14,15]. Unlike several other
MMPs that are localised predominantly in tumor stroma
[7,20], tumor cells themselves appear to express MMP-10
[8,19–21]. Overexpression of MMP-10 has been demon-
strated in several human tumors of epithelial origin including
head and neck, esophageal and oral squamous cell carci-
noma (SCC), and squamous and basal cell carcinomas of
the skin [19,20,22,23]. Recently, a small study (six cases)
also demonstrated increased levels of MMP-10 mRNA in
recurrences of human NSCLC following surgical resection
(five of six cases) [24], indicating a potential role for MMP-10
in the development of human NSCLC. The expression profile
of MMP-10 in several human tumors, coupled with broad
substrate specificity [14,15] and expression in several stages
of the tumorigenic process [20,22,23], suggests MMP-10
as a potential tumor marker and a predictor of clinical
behavior, and supports MMP-10 inhibition as a valid thera-
peutic strategy.
The aim of this study was to determine the protein
expression and activity of MMP-10 in NSCLC, the relation-
ship between MMP-10 and clinicopathologic factors, and the
potential for utilising MMP-10 activity as a therapeutic strat-
egy for the treatment of human NSCLC.
Materials and Methods
Human Tissue Samples
A total of 66 formalin-fixed, paraffin-embedded NSCLC
specimens and 50 freshly resected specimens of NSCLC
was used for this study. In addition, the study also includes
11 histologically normal human lung tissue specimens, ex-
cised from patients with early-stage lung cancer but distant to
the tumor mass. Table 1 shows the histologic and physical
characteristics of the tumors analysed, all of which were
obtained following surgical resection. A number of neuroen-
docrine carcinoma (six samples) and sarcomas (three sam-
ples) were diagnosed among the specimens, and, although
not part of the NSCLC classification, are included for com-
parison. All experiments were performed after first obtaining
consent from the local research and ethics committee
according to Medical Research Council regulations. Prior
informed consent was also obtained from patients for studies
involving fresh tissues. Patient details were anonymised to
ensure confidentiality.
Human Tumor Xenografts
Human tumor cell lines were xenografted in mice under a
project license issued by the UK Home Office, following
UKCCCR guidelines. Female mice (nu/nu from an inbred
colony; B&K Universal, Hull, UK) 6 to 8 weeks old were
implanted subcutaneously with 2 to 3 mm3 fragments of
H460 (non small cell lung carcinoma, or NSCLC), COLO
205 (colon adenocarcinoma), or PC3 (prostate adenocarci-
noma) tumors. Resultant tumors were removed, and either
snap-frozen in liquid nitrogen or formalin-fixed and embed-
ded in paraffin wax.
Immunohistochemistry
Localisation of MMP-10 was assessed by immunohisto-
chemistry in 66 formalin-fixed, paraffin-embedded tissue
blocks of primary lung tumors and five blocks of histologically
normal lung tissue and the H460 human NSCLC tumor
xenograft. Briefly, sections were dewaxed in xylene and
rehydrated to water through graded alcohols. Heat-mediated
antigen retrieval was performed by microwaving the slides
for 20 minutes in citric acid buffer (0.01 M, pH 6.0). Endog-
enous peroxidase activity was quenched with freshly pre-
pared 1% hydrogen peroxide for 30 minutes at room
temperature. Nonspecific antibody binding was inhibited
using 5% normal horse serum for 20 minutes at room
temperature. Sections were then incubated for 90 minutes
at room temperature in a humidified atmosphere with the
primary monoclonal antibody raised against amino acids
342 to 476 of human MMP-10 (Clone 5E4; Novocastra
Laboratories, Newcastle, UK) diluted 1:50 in PBS. This
antibody was previously shown in our laboratory to be
specific for MMP-10, detecting both active and pro forms of
the enzyme by Western blot analysis. Negative staining
controls were performed using normal mouse IgG (Dako,
Ely, UK) in place of the primary antibody. After washing in
PBS, sections were incubated for 30 minutes at room
temperature with an anti–mouse biotinylated secondary
antibody (Vector Laboratories, Peterborough, UK), diluted
1:200 in PBS, washed in PBS, and followed by amplification
and detection using a Vectastain ABC kit according to the
manufacturer’s instructions (Vector Laboratories). Immuno-
complex visualisationwas performedusing 3,3V-diaminoben-
zidine (DAB) according to the manufacturer’s instructions
(Vector Laboratories). Sections were then counterstained
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with Harris’ hematoxylin and mounted in DPX mountant
(Sigma, UK).
Semiquantitative Analysis of Immunohistochemistry
Positive immunostaining was scored semiquantitatively
by two independent observers. The epithelial compartment
of each tumor section was assigned a score for intensity
and distribution of staining on a scale of 0 (no staining) to 4
(intense staining throughout section). A note of any specific
staining pattern was recorded for each section. Histologi-
cally normal human lung sections were analysed in the
same manner and assigned a score. The results were com-
pared for any relationships to clinicopatholigic parameters.
Isolation and Immunocapture of MMP-10
For analysis of the levels of active enzyme, MMP-10
protein was isolated from freshly resected clinical samples
of human NSCLCs (50 samples), histologically normal lung
tissues (10 samples), and human tumor xenografts (H460,
COLO 205, and PC3). All samples were immediately snap-
frozen in liquid nitrogen following excision and stored at
80jC until required. For MMP-10 isolation, each specimen
was weighed and homogenised in 4 vol (wt/vol) of homoge-
nisation buffer (20 mM Tris–HCl, pH 7.5, 125 mM NaCl,
and 0.01% Triton X-100) using a dounce homogeniser on
ice. Cell debris was then removed by centrifugation at 9000g
for 15 minutes at 4jC. To 200 ml of supernatant (represent-
ing 40 mg of tissue), 3 mg of primary anti–MMP-10 antibody
(rabbit polyclonal; NeoMarkers, Fremont, CA) was added
and incubated overnight at 4jC with constant agitation. Fifty
microliters of anti–rabbit secondary antibody conjugated to
magnetic beads (sheep anti–rabbit IgG magnetic beads;
Dynal, UK) was added to the suspension and the complex-
incubated at 4jC for 30 minutes. Immunocomplexed
MMP-10 was isolated by applying a magnetic field to the
tube to attract the magnetic beads. The isolated beads were
washed five times in PBS to remove any unbound material.
Once cleaned, the MMP-10 complex was resuspended in
100 ml of assay buffer (50 mM Tris–HCl, pH 7.5, 10 mM
CaCl2, 150 mMNaCl, and 0.05% Brij 35) and either analysed
immediately or stored at 20jC for later use.
Validation of the immunocaptured protein as being MMP-
10 was performed using sodium dodecyl sulfate polyacryl-
amide gel electrophoresis (SDS-PAGE) and Western blot
analysis of xenograft immunoprecipitates, a panel of clinical
samples, and recombinant MMP-10 protein (R&D Systems,
Abingdon, UK). Briefly, 20 ml of immunocaptured protein so-
lution was separated on SDS-PAGE gels. The gel was either
stained using Coomassie Blue solution (Sigma) to identify
isolated protein bands, or transferred to polyvinylidenedi-
fluoride (PVDF) for Western blot analysis. For Western blot
analysis, nonspecific protein binding to the membranes was
blocked using 2% enhanced chemiluminescence (ECL) ad-
vanced blocking reagent (Amersham, Bucks, UK) in PBS.
Table 1. Relationship between Immunohistochemical MMP-10 Expression and Clinicopathologic Features of Human NSCLC.
Characteristic All Samples
(n = 84)
Number of Paraffin-Embedded
Samples (n = 71)
Median MMP-10 Protein Expression
(± Interquartile Range)
P
Histologic type
Normal tissue 11 5 1.00 (0.67–1.00)
Adenocarcinoma 35 31 2.00 (2.00–3.85)
SCC 24 22 3.00 (2.00–4.00)
Large cell carcinoma 2 2 2.38 (2.00–2.75)
Neuroendocrine 6 6 2.00 (2.00–4.00)
Sarcoma 3 2 3.50 (3.00–4.00)
Unclassified carcinoma 3 3 2.00 (1.50–2.50)
Differentiation status
Normal tissue 11 5 1.00 (0.67–1.00)
Poor 24 21 3.00 (2.00–4.00)
Moderate 20 17 2.00 (2.00–3.35)
Well 2 2 3.25 (3.00–3.50)
Not stated 27 26 2.00 (2.00–3.75)
Tumor stage*
Normal tissue 11 5 1.00 (0.67–1.00)
pT1 6 5 3.00 (3.00–3.50)
pT2 44 33 2.00 (2.00–3.25)
.18
pT3 5 5 1.00 (0.75–2.50)
Not stated 18 12 4.00 (3.00–4.00) ND
Lymph node status*
Normal tissue 11 5 1.00 (0.67–1.00)
pN0 26 21 3.00 (2.00–3.50)
pN1 17 14 2.63 (2.00–3.70)
.93
pN2 13 11 2.88 (2.00–4.00)
pNX 17 9 3.0 (2.00–3.88) ND
Values represent median expression level of MMP-10 (± interquartile range). Statistical analyses were undertaken to assess differences between pathologic
factors in relation to MMP-10 expression. Values of P V .05 were considered significant.
ND = Not included in statistical analyses.
*Neuroendocrine tumors, unclassified carcinomas, and sarcomas not included in these analyses.
}
}
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The blots were then incubated with anti–MMP-10 monoclo-
nal antibody (5E4) diluted 1:1000 in PBS overnight followed
by HRP-conjugated rabbit anti–mouse secondary antibody
(Dako) diluted 1:2000 in PBS for 1 hour. Immunoreactive
bands were visualised using an ECL detection kit according
to the manufacturer’s instructions. Stained gels and chemi-
luminescence were detected using the Bio-Rad FX imaging
system.
Assay of MMP-10 Activity
MMP-10 activity was defined as the ability of the isolated
fraction to hydrolyse the fluorescent MMP-10 substrate,
Pro–Lys–Pro–Val–Glu–nVal–Trp–Arg–Lys(Dnp)–NH2
(R&D Systems). The assay was performed in a 96-well plate
by incubating 100 ml of tumor immunoprecipitate with 20 ml of
substrate (final concentration, 100 mM), for a total volume of
120 ml. Fluorescence was measured (excitation = 320 nm;
emission = 405 nm) following a 240-minute incubation using
a Cary Eclipse fluorescence spectrophotometer (Varian,
Walton-on-Thames, UK). Continuous monitoring showed
this to be the linear part of the enzymatic curve. A negative
reaction blank by omission of tumor homogenate was in-
cluded in all plates. For each sample, the relative activity
was calculated as the fluorescence obtained from the sam-
ple minus that obtained in the reaction blank following the
240-minute incubation. Activity was expressed as change in
fluorescence per hour per gram of tissue. The reproducibility
and reliability of the assay were determined using samples
obtained from three independent H460 preparations.
Because MMP-10 can exist in both pro and active forms,
the total potential MMP-10 activity was calculated from
samples demonstrating a range of MMP-10 protein expres-
sion as measured by immunohistochemistry. Analysis was
performed on five NSCLC tumor samples (three adenocar-
cinomas, two SCCs; all pT2 N0) and four histologically normal
tissues. Tumor immunoprecipitates were preincubated with
1 mM APMA (amino-phenylmercuric acetate) for 2 hours at
37jC to activate all pro–MMP-10 to active MMP-10. Activity
of MMP-10 was then measured as previously described.
Statistical Analyses
Statistical analysis was undertaken using the SPSS soft-
ware package, version 11.0 (SPSS Inc., Chicago, IL). In the
immunohistochemical study, because MMP-10 expression is
not normally distributed, the average expression values for
each category were reported as medians with interquartile
ranges. Differences between two independent groups were
determined by the Mann-WhitneyU test, and the significance
of differences between more than two groups was deter-
mined by Kruskal-Wallis one-way analysis. The threshold for
statistical significance was assigned at P = .05.
Results
Expression of MMP-10 in NSCLC
The immunostaining analysis of MMP-10 protein in hu-
man NSCLC (66 cases; summarised in Table 1) of various
histologies and histologically normal lung tissues (five cases)
is summarised in Figure 1. The majority of histologically
normal lung tissue sections analysed showed very low
MMP-10 expression (median = 1.00; Figure 1). In contrast,
MMP-10 was expressed at much higher levels in all histo-
logic type of NSCLC (Figure 1). The levels of MMP-10 were
found to be statistically higher in NSCLC than in histologi-
cally normal lung tissue (P = .01). Analysis in terms of
histologic tumor type showed that there was no significant
difference of MMP-10 expression according to histologic
type of tumor. Similarly, no statistical differences were ob-
served in MMP-10 expression between the types of car-
cinoma analysed, adenocarcinoma, SCC, and large cell
carcinoma (LCC). Figure 2 shows representative images
of MMP-10 expression in the various types of NSCLC and
normal lung tissues.
Expression of MMP-10 in all the tumors analysed herein
was primarily in the tumor mass rather than the surrounding
tumor stroma (Figure 2). Occasionally, expression could be
observed within the stromal region of the tumor, but in these
cases, staining appeared to be both weak and extracellular,
possibly relating to secreted active MMP-10.
Although a high expression of MMP-10 was observed in
NSCLC, no correlation was observed with evidence of lymph
node metastasis (P = 0.93; Table 1). Expression of MMP-10
appeared to show a negative correlation with increasing
pathologic tumor stage (pT1–pT2–pT3), but this was not
found to be statistically significant (P = 0.18; Table 1).
Presence of Active MMP-10 in NSCLC
Because MMP-10 can exist as both an inactive proen-
zyme and an active enzyme, we assessed the presence
of active MMP-10 in NSCLC (50 samples) of various his-
tologies (Table 1) and histologically normal lung tis-
sues (10 cases). Such analyses could not be achieved
Figure 1. Immunohistochemical expression of MMP-10 protein in human lung
cancers and histologically normal lung tissues. In addition to samples of
NSCLC (adenocarcinoma, SCC, LCC, carcinoma), MMP-10 expression was
also analysed in both tumors of neuroendocrine origin and sarcomas as a
comparison. On the boxchart, thick horizontal lines through the boxes
represent median expression and the boxes represent the interquartile range.
SCC = squamous cell carcinoma; LCC = large cell carcinoma; carcinoma =
unclassified carcinoma.
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immunohistochemically due to the inability of this technique
to discriminate between the active and inactive forms of
the enzyme; therefore, an assay of function was required.
MMP-10 activity was defined as the ability of MMP-10 protein
immunoprecipitated from tumor lysates to cleave a fluores-
cently labeled substrate. Activity was quantified as the
fluorescence detected after the incubation of the substrate
with MMP-10 protein for 240 minutes and was expressed as
change in fluorescence per hour per gram of tissue.
Validation of the assay was performed using human
tumor xenograft tissues and recombinant MMP-10 proteins.
Immunoprecipitated protein separated by SDS-PAGE elec-
trophoresis demonstrated protein bands corresponding with
the size of pro– and active MMP-10 (recombinant) and IgG
(antibody) (data not shown). Western blot analysis confirmed
the identity of these protein bands as MMP-10 (Figure 3).
Although bands corresponding to pro –MMP-10 were
detected in all lanes, active MMP-10 protein was detected
only in the H460 (lung) and PC3 (prostate) xenograft lysates
(Figure 3), in agreement with the high levels of enzyme
activity detected in these xenografts. Reproducibility of the
activity assay was confirmed using independent H460 lysate
preparations (n = 3), with a mean activity of 221.3 ± 10.3
fluorescence units/hr per gram of tissue.
Measurable MMP-10 activity was detected in 42 of
50 specimens of lung cancer (median = 2.90 fluorescence
units). No relationship was observed between histologic type
of tumor and levels of active MMP-10 (Table 2). In contrast,
measurable MMP-10 activity was detected in 2 of 10 speci-
mens of histologically normal lung tissues (median activity =
0.0; Table 2). Although the majority of normal lung tissues
examined demonstrated low or negative protein expression
(Figure 1) and activity (Table 2) of MMP-10, one sample
showed an activity higher than the rest (31.2 fluorescence
units/hr per gram of tissue). This sample was obtained from
the same patient as the SCC, demonstrating the highest
activity (265 fluorescence units/hr per gram of tissue). Al-
though histologically normal, the enzyme activity in this
sample is likely to be as a consequence of the adjacent
highly active tumor.
Figure 2. Immunohistochemical results of MMP-10 protein expression in NSCLC (A–E) and histologically normal lung tissues (F). MMP-10 was expressed
predominantly in the tumor mass in all types of NSCLC; nonkeratinising (A) and keratinising (B) squamous lung carcinoma, poorly differentiated (C) and well-
differentiated (D) adenocarcinoma, and large cell carcinoma (E). No immunoreactivity for MMP-10 is observed in a histologically normal lung tissue specimen (F).
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Verification of a relationship between measured fluores-
cent cleavage activity and the appearance of active MMP-10
in the NSCLC tumor samples was undertaken using a
representative panel of human clinical samples. Protein
bands corresponding to both pro and active MMP-10 were
detected by Western blot analysis in the clinical samples
(Figure 4). Protein expression levels, as measured by im-
munohistochemistry, correlated with the amount of pro–
MMP-10 detected by Western blot analysis (Figure 4). The
presence and levels of active MMP-10 detected by Western
blot analysis also corresponded with the proteolytic activity
detected in the various samples (Figure 4). This further
supports the measured proteolytic activity as being repre-
sentative of MMP-10 activity.
In agreement with the immunohistochemical analysis, no
relationship was observed between MMP-10 activity and
either the tumor stage (pT status) or presence of local inva-
sion to the lymph node (pN status) (Table 2). To measure
total potential MMP-10 activity, selected samples were incu-
bated with APMA to activate pro–MMP-10 to active MMP-
10. No significant increase in MMP-10 activity was observed
in those samples exhibiting low MMP-10 expression by
immunohistochemistry (Table 3). Conversely, samples
expressing high levels of MMP-10 by immunohistochemistry
demonstrated a higher level of potential MMP-10 activity
(Table 3). In the histologically normal tissues examined, only
one sample demonstrated a significant increase in activity
following APMA incubation. In contrast, total levels of MMP-
10 activity were significantly higher in the tumor samples
analysed.
Discussion
Degradation of the ECM is essential for growth, vascularisa-
tion, spread, and invasion of tumors. Although many
enzymes are known to be involved, the MMPs are believed
to be the central mediators of this process. Within tumors,
MMPs can exist in two forms: as an inactive proenzyme or as
a proteolytically activated form. To address whether MMP-10
was a suitable target for therapeutic intervention, expression
and activity of MMP-10 were assessed in NSCLCs and
compared to that of histologically normal lung tissues.
Overexpression of MMP-10 has been shown in several
malignancies including head and neck carcinoma, oral car-
cinoma, esophageal carcinoma, skin cancer [19–21,23,24]
and, now, in several histologic types of human lung cancer.
The expression of MMP-10 protein in human NSCLC, its
relationship to tumor characteristics, and the presence of
active MMP-10 have not been previously reported. In this
study, MMP-10 expression and activity were significantly
Figure 3. Specificity of immunocapture technique for MMP-10. Western blot
analyses were undertaken of proteins isolated from both human tumor
xenograft lysates and recombinant MMP-10 protein. Pro–MMP-10 is present
in all lanes and active MMP-10 is present in only H460 and PC3 lysates, in
agreement with activity assays. Colo205 = human colon adenocarcinoma
xenograft; H460 = human non small cell lung carcinoma xenograft; PC3 =
prostate adenocarcinoma xenografts.
Table 2. Relationship between Activity Levels of MMP-10 and Clinicopatho-
logic Features of Human NSCLC.
Pathologic Parameter Number
of Cases
(n = 59)
Median MMP-10 Activity
[Dfluorescence/hr Per Gram of Tissue]
(Range of Activity)
P
Histologic type
Normal lung 10 0 (0–31.2)
Adenocarcinoma 29 10.0 (0.0–216.3)
SCC 13 24.4 (0.0–265.0)
Neuroendocrine 5 16.9 (1.9–28.1)
Sarcoma 2 78.4 (50.6–106.3)
Tumor stage*
pT1 4 40.0 (6.25–121.88)
pT2 36 15.3 (0.0–265.0) .55
pT3 2 12.2 (10.0–14.4)
Lymph node status*
pN0 17 20.6 (0.0–200.6)
pN1 10 10.3 (0.0–265.0) .46
pN2 8 27.2 (0.0–123.1)
pNX 8 59.7 (0.0–216.3) ND
Values are expressed as the median proteolytic activity (and range) in the
clinical samples. Activity is expressed as change in fluorescence units per
hour per gram of tissue. Statistical analyses were undertaken to assess
differences in MMP-10 activity between clinicopathologic features. Values of
P V .05 were considered significant.
ND = Not done.
*Neuroendocrine tumors and sarcomas were not included in these analyses.
Figure 4. Relationship between the presence of pro– and active MMP-10,
immunohistochemical analyses, and proteolytic activity in human clinical
samples. Pro–MMP-10 is present in all lanes and corresponds to the
expression levels of pro –MMP-10 detected by immunohistochemistry.
Proteolytic activity of the immunocaptured protein, as measured by change
in fluorescence per hour per gram of tissue, relates well to the presence of
active MMP-10. Tum = NSCLC specimen; Norm = histologically normal lung
tissue; pro = pro–MMP-10; active = active MMP-10.
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higher in all histologic types of NSCLC compared to histo-
logically normal lung tissues (Figure 1). In contrast to several
other MMPs [15], MMP-10 protein was predominantly
expressed in the tumor mass rather than the surrounding
stromal fibroblasts (Figure 2), an observation previously
reported in other tumor types [19,20]. Although the anti-
bodies used in this study had previously been shown to
detect both pro and active MMP-10, the cytoplasmic distri-
bution of MMP-10 observed in the archival wax embedded
samples is likely to reflect only inactive pro–MMP-10 and not
secreted active MMP-10, as suggested by Western blot
analysis (Figure 4). This theory is supported by the low levels
of extracellular MMP-10 protein detected by immunohisto-
chemistry in this study. Furthermore, even though both
MMP-10 expression and activity were increased in NSCLC
over normal lungs, in the several cases where both fresh and
wax-embedded tissue were available, only a weak correla-
tion was observed between MMP-10 expression and activity
(data not shown). In the samples treated with APMA, in
which pro–MMP-10 is converted to active MMP-10, samples
demonstrating a higher expression of MMP-10 showed a
greater ability to cleave the fluorogenic substrate. In contrast,
samples demonstrating absent or low expression of MMP-10
showed no significant increase in fluorescence. This result
further confirmed the clear differential in MMP-10 activity
between histologically normal lungs and NSCLC, and sup-
ported the presence of both pro and active MMP-10 in
NSCLC samples. These observations highlight the caution
that should be employed when attempting to relate mRNA or
immunohistochemical expression studies of MMP to clinical
features or function without prior consideration of proteolytic
MMP activity.
Conversely to the majority of MMPs that show a relation-
ship to tumor invasion or tumor stage, we observed no such
relationship between either MMP-10 expression or activity,
and either tumor histology, pT status, or pN status in NSCLC.
This observation is in agreement with previous studies of
cutaneous and oral SCC in which MMP-10 was not associ-
ated with malignant cell invasion [19,20]. Recently, upregu-
lated MMP-10 expression was suggested to relate to the
recurrence of stage IB (pT2, pN0, and pM0) lung cancer [24].
Although this conclusion was based on only a small sample
population, no such analysis could be undertaken in our
study due to the management of recurrent tumors by che-
motherapy as opposed to surgical resection. Taken together,
our data, demonstrating a lack of a correlation between
MMP-10 and either pT or pN status and that of others,
suggests that MMP-10 is involved in remodelling of the
ECM associated with the growth and expansion of the
neoplastic cell mass, rather than with either invasion to other
sites or progression to metastatic disease in several tumor
types [19,20], including NSCLC [24].
During the course of reepithelialisation of cutaneous
wounds, MMP-10 protein is expressed by migrating kerati-
nocytes and is central to successful wound healing [25]. In
this situation, MMP-10 expression is induced by cytokines
rather than cell contact with the dermal matrix. Interestingly,
those cells shown to express MMP-10 in the wound were
also shown to synthesize laminin-5 [25], an ECM protein
central to cell migration and wound closure following tissue
injury [26]. Importantly for this study, laminin-5 overexpres-
sion has been observed at the invasive tumor–stromal
interface of several different tumor types, including NSCLC,
implicating a role for laminin-5 in tumor growth and stromal
invasion [19,26–28]. In epithelial skin cancers, MMP-10
expression is only observed in laminin-5–positive tumor
cells [20], an observation in agreement with wound healing
studies [25] and indicative of a close relationship between
these two proteins. Although coexpression of these proteins
is often observed, cleavage of laminin-5 by MMP-10 and the
interplay between the proteins have not yet been shown
in vivo [20,25]. With reference to this study, laminin-5 is
frequently overexpressed in lung adenocarcinomas and is
associated with vascular invasion but not with nodal involve-
ment, lymphatic invasion, pleural invasion, or pathologic
tumor stage [26]—a profile similar to that observed with
MMP-10 in our study. In lung adenocarcinomas, laminin-5
overexpression is associated with disease recurrence and a
poor prognosis [26]. Based on these studies, laminin-5 over-
expression was suggested to occur at a relatively early
stage of lung tumor formation and shows no relationship
to lymphatic invasion or metastases [26]—a theory support-
ive of our observations with MMP-10. Therefore, if MMP-10
is an early event in lung tumor formation, is involved in
tumor growth rather than invasion, and associates with a
poor prognosis, targeting of MMP-10 using either specific
Table 3. Measurement of Total Potential MMP-10 Activity and Relationship to Immunohistochemical MMP-10 Expression.
Tumor Type MMP-10 Protein
Expression
MMP-10 Activity Prior to APMA Incubation
[Dfluorescence/hr Per Gram of Tissue]
MMP-10 activity After APMA Incubation
(Potential Activity) [Dfluorescence/hr Per Gram of Tissue]
Normal lung 0.7 0 0
Normal lung 1.0 0 0
Normal lung 1.3 0 0.6
Normal lung 3.0 0 7.6
Adenocarcinoma 1.2 0 0
Adenocarcinoma 2.0 20.6 42.4
SCC 2.0 24.4 36.3
Adenocarcinoma 3.25 60.6 76.6
SCC 3.0 121.3 121.3
APMA activation was used to convert inactive pro–MMP-10 into its active form, allowing the measurement of the total potential MMP-10 activity of the sample. The
ability of the sample to cleave a specific fluorogenic substrate was used to assess the levels of active MMP-10 and total potential MMP-10 activity in each sample.
Values are expressed as the change in fluorescence units per hour per gram of tissue.
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inhibitors or targeted therapeutics may be a valuable ap-
proach for the treatment of NSCLC. Additional studies are
necessary to address these questions.
The observation that MMPs themselves can activate one
another suggests a hierarchy among the MMP family and
implies the existence of an MMP activation cascade [8,29].
A central role for MMP-10 in this process is demonstrated
by its ability to cleave several proMMPs including MMP-1,
MMP-7, MMP-8, MMP-9, and MMP-13 [8,29]. Taken togeth-
er, the localisation of MMP-10 to the tumor mass and the lack
of correlation to tumor clinicopathologic factors, this broad
activity suggests an upstream and potential ‘‘initiator’’ role for
MMP-10 in the MMP cascade. This hypothesis is further
supported by proteolytic activation of MMP-10 by urokinase
plasminogen activator (uPA) coupled with an apparent lack
of evidence supporting MMP-10 activation by other MMPs
[30,31]. Taken together with the observation that MMP-10 is
expressed and active in the majority of NSCLC samples
analysed, this further supports MMP-10 as a potential target
for therapeutic intervention.
Over the last few years, the identification of MMPs as
being tumor-specific and central to tumor development and
spread resulted in the development of MMP inhibitors as
anticancer therapeutics. Until recently, clinical trials using
these inhibitors have been disappointing, with very little
success [32]. One of the main problems attributed to the
failure of these compounds was their broad-spectrum inhi-
bition of MMPs and subsequent activity against normal
cellular processes [32]. In addition, these drugs were tested
in late-stage cancer trials and so would bypass MMPs
involved in the early stages of cancer, such as MMP-10
[32]. Therefore, it is reasonable to postulate that inhibitors
with specificity against specific MMPs, such as MMP-10,
may be a better approach for the future. Recently, new
classes of MMP mediated therapeutics have been sug-
gested, including gene-targeted strategies and MMP-activat-
ed cytotoxics, which offer alternative approaches for
anticancer drug development. A greater understanding of
MMP expression, their activity profiles, and interrelationships
between one another is required to design more specific,
viable, and potent MMP-mediated therapies for the treatment
of human tumors, including NSCLC [32,33].
In conclusion, this is the first study showing the expres-
sion and activity of MMP-10 in human NSCLC. Unlike the
majority of MMPs, MMP-10 does not associate with tumor
invasion but instead may play a role in the growth and
development of the tumor mass in NSCLC. Further evalua-
tion of MMP-10 activity is required to address the proteolytic
levels of MMP-10 in tumor tissue, quantify MMP-10 levels,
establish any relationship between MMP-10 and prognosis,
and establish the viability of MMP-10 as a target for thera-
peutic intervention in human NSCLC.
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